288-99-3

Usage

Uses

Used in Pharmaceutical Industry:
Oxdiazole is used as a therapeutic agent for its antibacterial, anti-mycobacterial, antitumor, antiviral, and antioxidant activities. It modulates various biological pathways and demonstrates synergistic effects when combined with conventional drugs, enhancing their efficacy and sensitivity.
Used in Chemical Industry:
Oxdiazole is used as a building block in the synthesis of various compounds due to its electron-deficient nature and diverse pharmacological properties.
Used in Pesticide Industry:
Oxdiazole derivatives, such as oxadiazolinones, are used as insecticides and herbicides, providing effective pest control.
Used in Diagnostic Industry:
One of the oxadiazole derivatives, (2-[4-biphenylyl]-5-[4-tert-butylphenyl])-1,3,4-oxadiazole, is used as a scintillator in diagnostic applications.
Used in Optoelectronics Industry:
2,5-Disubstituted-1,3,4-oxadiazoles are used in the development of laser dyes, optical brighteners, scintillators, and electrophotographic photoconductors due to their fluorescence properties.
Used in Explosives Industry:
2,5-Dipicryl-1,3,4-oxadiazole has been reported as an explosive, showcasing its potential in this field.
Used in Corrosion Inhibition:
2-Aryl-5-oxadiazoline-5-thiones are used to inhibit corrosion in mild steel by acid solutions, providing protection against wear and tear.
Used in Liquid Crystal Industry:
A series of liquid crystals based on 1,3,4-oxadiazoles have been prepared and used to study the flexoelectric effect in guest/host mixtures, contributing to the advancement of liquid crystal technology.

Preparation

A solution of potassium hydroxide (4 pellets) was made in absolute ethanol (40ml) & poured into a round bottom flask. 10g of prepared hydrazide and 10ml of carbon disulphide was added in the round bottom flask. Condenser was adjusted and allowed to reflux for 6-8 hours. Reaction progress was checked at regular intervals by using TLC procedure with the use of varying ratio of n-hexane & ethyl acetate. As the reaction got completed, 20ml of chilled distilled water and a very small amount of dil. Sulfuric acid (H2SO4) to maintain the pH 2-3 in order to remove un-reacted base. Solid precipitates were obtained on vigorous shaking and filtered. Product was dried, collected &calculated.

Chemical Reactivity

Electrophilic substitution to 1,3,4-oxadiazole is unusual because electron density at the C2-and C5-positions is low. Electrophilic substitution is facile in aryl group present as substituent in lieu of 1,3,4-oxadiazole ring. Nucleophilic substitution reactions are uncommon in 1,3,4-oxadiazoles but ring cleavage is very common.

InChI:InChI=1/C2H2N2O/c1-3-4-2-5-1/h1-2H

Upstream product

• 6699-99-6 N'-formyl-formohydrazonic acid ethyl ester 
• 628-36-4 diformylhydrazine 

Downstream Products

• 725-12-2 2,5-bis-(phenyl)-1,3,4-oxadiazole 

Relevant academic research and scientific papers

Functionalization of 1,3,4-Oxadiazoles and 1,2,4-Triazoles via Selective Zincation or Magnesiation Using 2,2,6,6-Tetramethylpiperidyl Bases

We report the metalation of the 1,3,4-oxadiazole and 1,2,4-triazole scaffolds via regioselective zincation or magnesiation using the TMP bases (TMP = 2,2,6,6-tetramethylpiperidyl) TMP2Zn·2LiCl, TMP2Zn·2MgCl2·2LiCl, TMPMgCl

Catalytic Enantioselective Double Carbopalladation/C?H Functionalization with Statistical Amplification of Product Enantiopurity: A Convertible Linker Approach

Combining a catalytic enantioselective reaction with dimerization in a single operation is an efficient way to upgrade the enantiomeric excesses (ee) of the product. Palladium-catalyzed reaction of N-(2-iodophenyl)-N-methyl methacrylamide derivatives with

Improved synthesis and characterisation of 1,3,4-oxadiazole

Synthetic approaches to 1,3,4-oxadiazole have been investigated and an improved method involving dehydration of N,N′-diformylhydrazine with P2O5 in polyphosphoric acid is described. The 13C NMR spectrum of this compound is reported for the first time including determination of 1JC-H and 3J C-H. ARKAT-USA, Inc.

Oxazole PPAR antagonist

A method is disclosed for rational design of a PPAR, FXR, LXR-alpha, or LXR-beta antagonist comprising chemical modification of a PPAR, FXR, LXR-alpha, or LXR-beta agonist to: a) prevent formation of a hydrogen bond between the agonist and tyrosine or histidine, or tryptophan involved in receptor activation; and/or b) displace the tyrosine or histidine, or tryptophan involved in receptor activation from its agonist bound position. Preferably, little or no additional changes are made in the structure of the agonist so that the resulting antagonist is a close structural analogue of the agonist. Specific examples of PPAR gamma antagonists designed and prepared using the method of this invention are compounds of Formula (I) or (II), or pharmaceutically acceptable salts or solvates thereof, where in Formula (I) X is O, S, or NH; and R is methyl, ethyl, n-propyl, i-propyl, cyclopropyl, n-butyl, phenyl, or —CH2OCH3and wherein in Formula (II) X is C or N; and R is methyl, ethyl, n-propyl, i-propyl, —CH2OCH3, or —CO2CH3.

Trisubstituted heterocyclic compounds and their use as fungicides

Compounds of general formula (I): in which:Het represents a five or six membered saturated, partially unsaturated or aromatic ring containing between one and six heteroatoms of the group N, O, S, in which the heterocycle is substituted in an adjacent manner with -P-Q1-T-Q2, -GZ and Y, such that the substituant -GZ is adjacent to both. the other substituants being as defined in the description,process for preparing these compounds,fungicidal compositions comprising these compounds,processes for treating plants by applying these compounds or compositions.

Substituted amino methyl factor Xa inhibitors

The present application describes substituted-aminomethyl substituted compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

Heteroaryl-phenyl substituted factor Xa inhibitors

The present application describes heteroaryl-phenyl substituted compounds and derivatives thereof, or pharmaceutically acceptable salt or prodrug forms thereof, which are useful as inhibitors of factor Xa.

Heteroaryl- phenyl heterobicyclic factor Xa inhibitors

The present application describes heteroaryl-phenyl heterobicycles and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor Xa

The present application describes inhibitors of factor Xa of formula I: or pharmaceutically acceptable salt forms thereof, wherein W, W1, W2, and W3may be N or C and J, Ja, and Jbcombine to form a substituted carbocycle or heterocycle.

6-membered aromatics as factor Xa inhibitors

The present application describes 6-membered aromatics of formula I: or pharmaceutically acceptable salt forms thereof, wherein D may be CH2NH2 or C(=NH)NH2, which are useful as inhibitors of factor Xa.